Drugs / 18F-fluorofuranylnorprogesterone
18F-fluorofuranylnorprogesterone
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06086704 | Sep 2024 → Aug 2028 expected | breast cancer | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT06067503 | Apr 2024 → Aug 2026 overdue | breast lobular carcinoma, metastatic malignant neoplasm | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT05483023 | Feb 2024 → Jun 2026 | complex endometrial hyperplasia, endometrial cancer | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05480995 | Jan 2023 → Aug 2026 overdue | endometriosis | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 2 | NCT03212170 | Dec 2017 → Nov 2024 | invasive breast carcinoma | University of Wisconsin, Madison | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]Fluorofuranylnorprogesterone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03212170 ↗ |
| Known as | 18F-FFNP | “18F-fluorofuranylnorprogesterone (18F-FFNP)” NCT06086704 ↗ |
| Known as | FFNP | “The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by...” NCT06067503 ↗ |
| Modality | Diagnostic / imaging agent | “18F-fluorofuranylnorprogesterone tracer” NCT05480995 ↗ |
| Route | Intravenous | “IV slow infusion” NCT06067503 ↗ |